Status: Recruiting
A Study of Mavorixafor in Participants With Congenital and Acquired Primary Autoimmune and Idiopathic Chronic Neutropenic Disorders Who Are Experiencing Recurrent and/or Serious Infections
The purpose of this study is to demonstrate the efficacy and evaluate the safety and tolerability of mavorixafor in participants with congenital or acquired primary autoimmune and idiopathic chronic neutropenic disorders who are experiencing recurrent and/or serious infections as assessed by demonstrating its clinical benefit and increasing levels of circulating neutrophils.
Participants needed: 176
Trial details
Phase: Phase 3Age: 12+Biological sex: AllType: InterventionalSponsor: X4 PharmaceuticalsUpdated: Aug 6, 2026Locations: 114
Eligibility criteria
Diagnosis of congenital or acquired primary autoimmune and idiopathic chronic ne... [+13]
Hypersplenism [+16]